David S Miller1, Virginia L Filiaci2, Robert S Mannel3, David E Cohn4, Takashi Matsumoto5, Krishnansu S Tewari6, Paul DiSilvestro7, Michael L Pearl8, Peter A Argenta9, Matthew A Powell10, Susan L Zweizig11, David P Warshal12, Parviz Hanjani13, Michael E Carney14, Helen Huang2, David Cella15, Richard Zaino16, Gini F Fleming17. 1. University of Texas Southwestern Medical Center, Dallas, TX. 2. NRG Oncology, Clinical Trial Development Division, Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY. 3. The Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK. 4. Arthur G. James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH. 5. Ehime University School of Medicine, Ehime, Japan. 6. Division of Obstetrics and Gynecology, University of California, Irvine Medical Center, Orange, CA. 7. Women and Infants Hospital, Providence, RI. 8. Stony Brook University Hospital, Stony Brook, NY. 9. University of Minnesota, Minneapolis, MN. 10. Gynecologic Oncology, Washington University School of Medicine, St Louis, MO. 11. University of Massachusetts Memorial Medical Center, Worcester, MA. 12. Cooper Hospital/University Medical Center, Camden, NJ. 13. Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington, PA. 14. John A. Burns School of Medicine, University of Hawaii Cancer Center, Honolulu, HI. 15. Northwestern University Feinberg School of Medicine, Chicago, IL. 16. Penn State University, Hershey, PA. 17. The University of Chicago Medicine, Chicago, IL.
Abstract
PURPOSE: Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. METHODS: GOG0209 was a phase III, randomized, noninferiority, open-label trial. Inclusion criteria were stage III, stage IV, and recurrent endometrial cancers; performance status 0-2; and adequate renal, hepatic, and marrow function. Prior radiotherapy and/or hormonal therapy were permitted, but chemotherapy, including radiosensitization, was not. Patients were treated with doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 (day 1), followed by paclitaxel 160 mg/m2 (day 2) with granulocyte colony-stimulating factor or paclitaxel 175 mg/m2 and carboplatin area under the curve 6 (day 1) every 21 days for seven cycles. The primary endpoint was overall survival (OS; modified intention to treat). Progression-free survival (PFS), health-related quality of life (HRQoL), and toxicity were secondary endpoints. RESULTS: From 2003 to 2009, 1,381 women were enrolled. Noninferiority of TC to TAP was concluded for OS (median, 37 v 41 months, respectively; hazard ratio [HR], 1.002; 90% CI, 0.9 to 1.12), and PFS (median, 13 v 14 months; HR, 1.032; 90% CI, 0.93 to 1.15). Neutropenic fever was reported in 7% of patients receiving TAP and 6% of those receiving TC. Grade > 2 sensory neuropathy was recorded in 26% of patients receiving TAP and 20% receiving TC (P = .40). More grade ≥ 3 thrombocytopenia (23% v 12%), vomiting (7% v 4%), diarrhea (6% v 2%), and metabolic (14% v 8%) toxicities were reported with TAP. Neutropenia (52% v 80%) was more common with TC. Small HRQoL differences favored TC. CONCLUSION: With demonstrated noninferiority to TAP, TC is the global first-line standard for advanced endometrial cancer.
PURPOSE: Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. METHODS: GOG0209 was a phase III, randomized, noninferiority, open-label trial. Inclusion criteria were stage III, stage IV, and recurrent endometrial cancers; performance status 0-2; and adequate renal, hepatic, and marrow function. Prior radiotherapy and/or hormonal therapy were permitted, but chemotherapy, including radiosensitization, was not. Patients were treated with doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 (day 1), followed by paclitaxel 160 mg/m2 (day 2) with granulocyte colony-stimulating factor or paclitaxel 175 mg/m2 and carboplatin area under the curve 6 (day 1) every 21 days for seven cycles. The primary endpoint was overall survival (OS; modified intention to treat). Progression-free survival (PFS), health-related quality of life (HRQoL), and toxicity were secondary endpoints. RESULTS: From 2003 to 2009, 1,381 women were enrolled. Noninferiority of TC to TAP was concluded for OS (median, 37 v 41 months, respectively; hazard ratio [HR], 1.002; 90% CI, 0.9 to 1.12), and PFS (median, 13 v 14 months; HR, 1.032; 90% CI, 0.93 to 1.15). Neutropenic fever was reported in 7% of patients receiving TAP and 6% of those receiving TC. Grade > 2 sensory neuropathy was recorded in 26% of patients receiving TAP and 20% receiving TC (P = .40). More grade ≥ 3 thrombocytopenia (23% v 12%), vomiting (7% v 4%), diarrhea (6% v 2%), and metabolic (14% v 8%) toxicities were reported with TAP. Neutropenia (52% v 80%) was more common with TC. Small HRQoL differences favored TC. CONCLUSION: With demonstrated noninferiority to TAP, TC is the global first-line standard for advanced endometrial cancer.
Authors: K M Greven; W J Curran; R Whittington; J Fanning; M E Randall; J Wilder; A J Peters Journal: Int J Radiat Oncol Biol Phys Date: 1989-07 Impact factor: 7.038
Authors: Marcus E Randall; Virginia L Filiaci; Hyman Muss; Nick M Spirtos; Robert S Mannel; Jeffrey Fowler; J Tate Thigpen; Jo Ann Benda Journal: J Clin Oncol Date: 2005-12-05 Impact factor: 44.544
Authors: Holly H Gallion; Virginia L Brunetto; Michael Cibull; Samuel S Lentz; Gary Reid; John T Soper; Robert A Burger; Willie Andersen Journal: J Clin Oncol Date: 2003-10-15 Impact factor: 44.544
Authors: Howard D Homesley; Virginia Filiaci; Susan K Gibbons; Harry J Long; David Cella; Nick M Spirtos; Robert T Morris; Koen DeGeest; Roger Lee; Anthony Montag Journal: Gynecol Oncol Date: 2008-12-23 Impact factor: 5.482
Authors: D Lorusso; G Ferrandina; N Colombo; S Pignata; A Pietragalla; C Sonetto; C Pisano; M T Lapresa; A Savarese; P Tagliaferri; D Lombardi; S Cinieri; E Breda; I Sabatucci; R Sabbatini; C Conte; S C Cecere; G Maltese; G Scambia Journal: Gynecol Oncol Date: 2019-10-31 Impact factor: 5.482
Authors: Casey M Cosgrove; Floor J Backes; David O'Malley; Kristin L Bixel; Adrian A Suarez; Jeffrey M Fowler; Larry J Copeland; Paul J Goodfellow; David E Cohn Journal: Oncologist Date: 2021-08-25
Authors: Kristina W Thiel; Eric J Devor; Virginia L Filiaci; David Mutch; Katherine Moxley; Angeles Alvarez Secord; Krishnansu S Tewari; Megan E McDonald; Cara Mathews; Casey Cosgrove; Summer Dewdney; Carol Aghajanian; Megan I Samuelson; Heather A Lankes; Robert A Soslow; Kimberly K Leslie Journal: J Clin Oncol Date: 2022-06-03 Impact factor: 50.717
Authors: David M O'Malley; Giovanni Mendonca Bariani; Philippe A Cassier; Aurelien Marabelle; Aaron R Hansen; Ana De Jesus Acosta; Wilson H Miller; Tamar Safra; Antoine Italiano; Linda Mileshkin; Lei Xu; Fan Jin; Kevin Norwood; Michele Maio Journal: J Clin Oncol Date: 2022-01-06 Impact factor: 50.717